DIMERIX LIMITED (DXB)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

DXB

DXB - DIMERIX LIMITED

Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0
Index: ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.53

16 Oct
2025

0.005

OPEN

$0.53

0.95%

HIGH

$0.54

338,292

LOW

$0.53

OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NEU . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS

- No Record -

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx-2.4
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx5.6 M
Book Value Per Share xxxxxxxxxxxxxxx2.2
Net Operating Cash Flow xxxxxxxxxxxxxxx39.0 M
Net Profit Margin xxxxxxxxxxxxxxx-237.20 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx-83.97 %
Return on Invested Capital xxxxxxxxxxxxxxx-83.78 %
Return on Assets xxxxxxxxxxxxxxx-21.50 %
Return on Equity xxxxxxxxxxxxxxx-83.97 %
Return on Total Capital xxxxxxxxxxxxxxx-201.24 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx39.0 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxxxxx0 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx68 M
Price To Book Value xxxxxxxxxxxxxxx25.73

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx0.0 M
Capex % of Sales xxxxxxxxxxxxxxx0.38 %
Cost of Goods Sold xxxxxxxxxxxxxxx-
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx37 M
Research & Development xxxxxxxxxxxxxxx27 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

0
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Petra Capital

09/10/2025

1

Buy

$1.46

175.47%

Dimerix has passed the first checkpoint toward the next interim analysis of its FSGS trial, with Parasol data aligning with its trial population. Parasol is a clinical study conducted by Amicus Therapeutics.

FSGS, or Focal Segmental Glomerulosclerosis, is a rare and serious kidney disease that causes scarring in the tiny filtering units inside the kidney.

Petra Capital notes the results confirm the FDA-approved 24-month proteinuria endpoint and suggest a new 12-month correlation that could support accelerated approval.

Dimerix and Amicus will meet the FDA in December 2025 to discuss this pathway. Subject to feedback and a blinded powering analysis, data could be unblinded in early 2026 to back an accelerated approval submission and trigger a milestone payment.

Petra Capital retains a Buy rating and $1.46 target.

FORECAST
Petra Capital forecasts a full year FY26 dividend of 0.00 cents and EPS of 0.90 cents.
Petra Capital forecasts a full year FY27 dividend of 0.00 cents and EPS of 0.50 cents.

DXB STOCK CHART